Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07105488 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

Study acronym: COMPASS 2-AD
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment closed, study ongoing Site details revised at 88 of 88 sitesv5 Show 1 more changeShow less
    • Site details revised at 88 of 88 sites
  2. Trial sites expanded: 55 → 88 locationsv4
  3. Trial sites expanded: 35 → 55 locationsv3
  4. Study sites: 7 to 35v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.
Trial Details
NCT Number NCT07105488
Lead Sponsor Bluefin Biomedicine, Inc.
Conditions Atopic Dermatitis (AD)
Enrollment 225 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov